All In Biotech

Drug Trial Radar · NCT01377844

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

Efficacy and Safety of EGT0001442 Compared With Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Diet and Exercise and up to One Oral Anti-diabetes Agent

Last checked: Nov 20, 2026Latest source record: Jul 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 288 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

288

Actual

Start

Dec 2011

Primary completion

Nov 2013

Study completion Dec 2013

Sponsor

Lead sponsor
TheracosIndustry
Sponsor type
Industry
First posted
Jun 21, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy of EGT0001442 in lowering glycosylated Hemoglobin (HbA1c, A laboratory test to diagnose three months average of blood sugar)levels at 24th week from baseline, when compared to placebo group(no diabetic medication given). The secondary aim of the study is to evaluate the efficacy of EGT0001442 in lowering fasting blood glucose at the weeks 2 and 24 and comparing the results with placebo group. This study assess the efficacy of EGT0001442 based on the proportion of subjects who reach the American Diabetes Association (ADA) target of HbA1c of \< 7% in EGT0001442 group and comparison with placebo. The study also evaluates the effect of EGT0001442 on systolic, diastolic pressures, body weight and compare with the respective placebo groups.This study also assess the change from baseline in HbA1c overtime, from week 1 to week 96. Finally, to assess the safety of EGT0001442 in the Type 2 Diabetic patients (adult/maturity onset).

Conditions

  • Diabetes Mellitus

Interventions

  • EGT0001442Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1c at 24 WeeksTime frame: Baseline and Week 24

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Site 5

    Buena Park, California

  • Site 4

    Los Angeles, California

  • Site 3

    Santa Ana, California

  • Site 1

    Hialeah, Florida

  • Site 9

    Berlin, New Jersey

  • Site 7

    Cary, North Carolina

  • Site 6

    Marion, Ohio

  • Site 8

    Munroe Falls, Ohio

  • Site 2

    Portland, Oregon

  • Site 11

    North Richland Hills, Texas

  • Site 7

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.